Invention Grant
US09086414B2 Phosphorylated C-ErbB2 as a superior predictive theranostic marker for the diagnosis and treatment of cancer
有权
磷酸化的C-ErbB2作为癌症诊断和治疗的优越预测因素
- Patent Title: Phosphorylated C-ErbB2 as a superior predictive theranostic marker for the diagnosis and treatment of cancer
- Patent Title (中): 磷酸化的C-ErbB2作为癌症诊断和治疗的优越预测因素
-
Application No.: US13003206Application Date: 2009-07-08
-
Publication No.: US09086414B2Publication Date: 2015-07-21
- Inventor: Emanuel F. Petricoin, III , Lance A. Liotta , Virginia Espina , Julia D. Wulfkuhle
- Applicant: Emanuel F. Petricoin, III , Lance A. Liotta , Virginia Espina , Julia D. Wulfkuhle
- Applicant Address: US VA Fairfax
- Assignee: George Mason Research Foundation, Inc.
- Current Assignee: George Mason Research Foundation, Inc.
- Current Assignee Address: US VA Fairfax
- Agent Geoffrey M. Karny
- International Application: PCT/US2009/049903 WO 20090708
- International Announcement: WO2010/006027 WO 20100114
- Main IPC: A61K39/395
- IPC: A61K39/395 ; A01N43/48 ; G01N33/53 ; G01N33/543 ; G01N33/574 ; C12Q1/68 ; A61K31/517 ; G01N1/30 ; A61K39/00
Abstract:
The present invention provides reliable methods to identify subsets of subjects with a cancer of epithelial origin characterized by a high level of phosphorylated c-erbB2 which does not correlate with the over-expression of total c-erbB2 as measured by IHC or FISH, for selection and inclusion for c-erbB2-direct treatment and therapy. Furthermore, the present invention provides a reliable method to determine whether a subject with a cancer of epithelial origin who has been determined to be c-erbB2 positive by IHC and by FISH should be excluded from c-erbB2-direct treatment because of a non-significant level of phosphorylated c-erbB2 in epithelial tumor tissue.
Public/Granted literature
Information query
